ScreenerHero

EDITEditas Medicine, Inc.

NAS · US · Healthcare · Biotechnology · editasmedicine.com
3.110USD-4.31%Mkt Cap: 477.63M $P/E: —

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap477.63M $
Enterprise Value255.39M $
Revenue (TTM)47.01M $
Gross Profit-37.95M $
Net Income (TTM)-160.06M $
Revenue/Share0.4640 USD
Last Price3.110 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS28106W1036
Valuation
P/E (Trailing)—
P/E (Forward)-3.90
PEG—
EV/EBITDA-3.15
EV/Revenue5.43
P/S9.61
P/B4.29
EPS (TTM)-0.59
EPS (Forward)-0.75
52W Range
1.66050% of range4.537
52W High4.537 USD
52W Low1.660 USD
Profitability
Gross Margin-80.75%
Oper. Margin-167.31%
EBITDA Margin-172.40%
Profit Margin-395.01%
ROE-586.56%
ROA-85.81%
Growth
Revenue Growth232.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-165.24M $
CapEx (TTM)607.00K $
FCF Margin-94.28%
FCF Yield-9.28%
Net Debt-196.13M $
Net Debt/EBITDA2.42
Balance Sheet
Debt/Equity0.66
Current Ratio3.19
Quick Ratio3.13
Book Value/Sh0.6860 USD
Cash/Share1.378 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.000 USD
Upside (mean)+92.9%
Target Range1.000 USD – 15.00 USD
$1.000+92.9% to mean$15.00
# Analysts9
Ownership
Shares Out.153.58M
Float115.50M
Insiders0.18%
Institutions79.20%
Short Interest
Short Ratio11.9d
Short % Float15.30%
Short % Out.15.28%
Shares Short23.46M
Short (prev mo.)22.47M
Technical
SMA 502.896 (+7.4%)
SMA 2002.587 (+20.2%)
Beta2.06
S&P 52W Chg18.16%
Avg Vol (30d)1.96M
Avg Vol (10d)2.77M
Technical Indicators
RSI (14)58.0
MACD0.0325
MACD Signal-0.0151
MACD Hist.+0.0476
BB Upper3.137 USD
BB Middle2.794 USD
BB Lower2.451 USD
BB Width24.55%
ATR (14)0.2052 USD
Vol Ratio (20d)1.09x